NCT05272826 - Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2031

Conditions

Multiple Myeloma

Interventions

DRUG

Iberdomide

Available as formulated capsules and administered as oral medication

DRUG

Bortezomib

Administered as subcutaneous injection

DRUG

Dexamethasone

Administered as oral medication

DRUG

Isatuximab

Administered as subcutaneous injection

Trial Locations (5)

RECRUITING

QEII Health Science Centre, Halifax

RECRUITING

London Health Sciences Centre, London

RECRUITING

Princess Margaret Hospital, Toronto

RECRUITING

Hôpital Maisonneuve-Rosemont, Montreal

RECRUITING

McGill University Health Centre, Montreal